Clinical trial · Observational
AMH, Glucose Intolerance and Metabolic Syndrome in PCOS
Anti-Müllerian Hormone and Its Association With Glucose Intolerance and Metabolic Syndrome in Women With Polycystic Ovary Syndrome
NCT02676518CI-TRIAL-00020832unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Association between serum anti-Mullerian hormone (AMH) level and prevalence of glucose intolerance and metabolic syndrome in women with polycystic ovary syndrome (PCOS)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| serum | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- polycystic ovary syndrome women
- description
- PCOS women diagnosed by Rotterdam criteria visiting the Gynecologic Unit at King Chulalongkorn Memorial Hospital and meet the inclusion criteria and no exclusion criteria of the study
- interventionNames
- Other: serum
Primary outcomes (1)
- measure
- Differences between serum AMH level between PCOS women with and without glucose intolerance and metabolic syndrome
- timeFrame
- 6 months
- description
- Any differences between mean of serum AMH levels in PCOS with and without glucose intolerance and metabolic syndrome
Secondary outcomes (2)
- measure
- Percentage of glucose intolerance in PCOS women
- timeFrame
- 6 months
- description
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: * PCOS diagnosed by Rotterdam criteria 2003 Exclusion Criteria: * Pregnancy * Previous any hormonal uses in the last 3 months * Previous hypoglycemic drugs or insulin-sensitising agents use in the last 3 months * Previous chemotherapy, ovarian surgery, pelvic irradiation * Menopause
References
Publications (0)
Data not yet available
No reference posted for this study.